ID   LS513
AC   CVCL_1386
SY   LS-513; LS 513
DR   CLO; CLO_0007407
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2134
DR   BioSample; SAMN03472554
DR   BioSample; SAMN10987976
DR   CCLE; LS513_LARGE_INTESTINE
DR   Cell_Model_Passport; SIDM00677
DR   ChEMBL-Cells; CHEMBL3308841
DR   ChEMBL-Targets; CHEMBL2366311
DR   CLS; 300457/p707_LS-513
DR   ColonAtlas; LS513
DR   Cosmic; 711275
DR   Cosmic; 724844
DR   Cosmic; 887230
DR   Cosmic; 907795
DR   Cosmic; 983740
DR   Cosmic; 1132570
DR   Cosmic; 1310942
DR   Cosmic; 1479582
DR   Cosmic; 1609478
DR   Cosmic; 1708410
DR   Cosmic; 1995492
DR   Cosmic; 2302000
DR   Cosmic-CLP; 907795
DR   DepMap; ACH-000007
DR   GDSC; 907795
DR   GEO; GSM513914
DR   GEO; GSM514301
DR   GEO; GSM887281
DR   GEO; GSM888356
DR   GEO; GSM1006222
DR   GEO; GSM1006223
DR   GEO; GSM1006224
DR   GEO; GSM1346849
DR   GEO; GSM1374638
DR   GEO; GSM1448141
DR   GEO; GSM1670062
DR   IARC_TP53; 21480
DR   KCLB; 22134
DR   LiGeA; CCLE_369
DR   LINCS_LDP; LCL-1338
DR   PharmacoDB; LS513_864_2019
DR   PRIDE; PXD005235
DR   PRIDE; PXD005354
DR   Wikidata; Q54903070
RX   PubMed=1389533;
RX   PubMed=1617643;
RX   PubMed=8895552;
RX   PubMed=9000147;
RX   PubMed=9000572;
RX   PubMed=11414198;
RX   PubMed=11526487;
RX   PubMed=12068308;
RX   PubMed=16418264;
RX   PubMed=16854228;
RX   PubMed=18258742;
RX   PubMed=20164919;
RX   PubMed=20570890;
RX   PubMed=20606684;
RX   PubMed=22460905;
RX   PubMed=23272949;
RX   PubMed=23932154;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=28854368;
RX   PubMed=29101300;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Doubling time: 20 hours (PubMed=25984343).
CC   Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=25926053; Sanger).
CC   Sequence variation: Homozygous for CTNNB1 p.Ala5_Ala80del (c.14_241del228) (ATCC).
CC   Sequence variation: Heterozygous for KRAS p.Gly12Asp (c.35G>A) (PubMed=12068308; PubMed=20570890; PubMed=24755471).
CC   Sequence variation: Has no TP53 mutation (PubMed=16418264).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.3%; Native American=0%; East Asian, North=4.01%; East Asian, South=0%; South Asian=0%; European, North=52.68%; European, South=43% (PubMed=30894373).
ST   Source(s): ATCC; CLS; Cosmic-CLP; KCLB; PubMed=25926053
ST   Amelogenin: X,Y
ST   CSF1PO: 10,13 (ATCC; Cosmic-CLP; KCLB; PubMed=25926053)
ST   CSF1PO: 10 (CLS)
ST   D13S317: 9,10
ST   D16S539: 12,13
ST   D18S51: 12,18
ST   D21S11: 30
ST   D3S1358: 15
ST   D5S818: 9,11 (ATCC; Cosmic-CLP; KCLB; PubMed=25926053)
ST   D5S818: 11 (CLS)
ST   D7S820: 8,11
ST   FGA: 19,21
ST   Penta D: 9,14
ST   Penta E: 5,18
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C5543; Cecum adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 26
//
RX   PubMed=1389533; DOI=10.1016/0959-8049(92)90031-V;
RA   Lahm H., Petral-Malec D., Yilmaz-Ceyhan A., Fischer J.R.,
RA   Lorenzoni M., Givel J.-C., Odartchenko N.;
RT   "Growth stimulation of a human colorectal carcinoma cell line by
RT   interleukin-1 and -6 and antagonistic effects of transforming growth
RT   factor beta 1.";
RL   Eur. J. Cancer 28:1894-1899(1992).
//
RX   PubMed=1617643;
RA   Suardet L., Gaide A.-C., Calmes J.-M., Sordat B., Givel J.-C.,
RA   Eliason J.F., Odartchenko N.;
RT   "Responsiveness of three newly established human colorectal cancer
RT   cell lines to transforming growth factors beta 1 and beta 2.";
RL   Cancer Res. 52:3705-3712(1992).
//
RX   PubMed=8895552; DOI=10.1002/(SICI)1097-0215(19960927)68:1<126::AID-IJC22>3.0.CO;2-8;
RA   Suardet L., Li C., Little J.B.;
RT   "Radio-induced modulation of transforming growth factor beta1
RT   sensitivity in a p53 wild-type human colorectal-cancer cell line.";
RL   Int. J. Cancer 68:126-131(1996).
//
RX   PubMed=9000147;
RA   Cottu P.H., Muzeau F., Estreicher A., Flejou J.-F., Iggo R.D.,
RA   Thomas G., Hamelin R.;
RT   "Inverse correlation between RER+ status and p53 mutation in
RT   colorectal cancer cell lines.";
RL   Oncogene 13:2727-2730(1996).
//
RX   PubMed=9000572;
RA   Hoang J.-M., Cottu P.H., Thuille B., Salmon R.J., Thomas G.,
RA   Hamelin R.;
RT   "BAT-26, an indicator of the replication error phenotype in colorectal
RT   cancers and cell lines.";
RL   Cancer Res. 57:300-303(1997).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=11526487; DOI=10.1038/sj.onc.1204611;
RA   Gayet J., Zhou X.-P., Duval A., Rolland S., Hoang J.-M., Cottu P.H.,
RA   Hamelin R.;
RT   "Extensive characterization of genetic alterations in a series of
RT   human colorectal cancer cell lines.";
RL   Oncogene 20:5025-5032(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=16854228; DOI=10.1186/1476-4598-5-29;
RA   Bandres E., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N.,
RA   Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J.;
RT   "Identification by real-time PCR of 13 mature microRNAs differentially
RT   expressed in colorectal cancer and non-tumoral tissues.";
RL   Mol. Cancer 5:29-29(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66-66(2012).
//
RX   PubMed=23932154; DOI=10.1016/j.radonc.2013.06.032;
RA   Salendo J., Spitzner M., Kramer F., Zhang X., Jo P., Wolff H.A.,
RA   Kitz J., Kaulfuss S., Beissbarth T., Dobbelstein M., Ghadimi M.,
RA   Grade M., Gaedcke J.;
RT   "Identification of a microRNA expression signature for
RT   chemoradiosensitivity of colorectal cancer cells, involving
RT   miRNAs-320a, -224, -132 and let7g.";
RL   Radiother. Oncol. 108:451-457(2013).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002-7002(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010;
RA   Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C.,
RA   Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M.,
RA   Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R.,
RA   Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.;
RT   "Genomic determinants of protein abundance variation in colorectal
RT   cancer cells.";
RL   Cell Rep. 20:2201-2214(2017).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//